A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants
← catalyst calendarNCT07532863 · readout in 220 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
400estimated
Sites
6
Countries
Indonesia, Malaysia, Philippines +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-13 | actual | When the study began enrolling |
| Primary completion | 2027-03-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-27 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetes Mellitus, Type 2
Intervention
- Other: No treatment given
Primary outcomes
what the primary-completion date above is the date OFCardiometabolic profile: Systolic blood pressure at baseline
measured At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: Waist circumference at baseline
measured At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: Hip circumference at baseline
measured At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: Height at baseline
measured At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: Weight at baseline
measured At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: Total cholesterol at baseline
measured At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: High-density lipoprotein cholesterol (HDL-C) at baseline
measured At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: Low-density lipoprotein cholesterol (LDL-C) at baseline
measured At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: Non High-density lipoprotein cholesterol (Non-HDL-C) at baseline
measured At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: Triglycerides at baseline
measured At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: Glycated haemoglobin (HbA1c) at baseline
measured At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: Fasting plasma glucose (FPG) at baseline
measured At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: estimated glomerular filtration rate (eGFR) at baseline
measured At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: Serum creatinine at baseline
measured At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Proportion of participants classified into CVD risk categories (very high, high, moderate or low risk) - Yes/No
measured At baseline: Status at the index date or, if unavailable, the closest record within the 12 months prior to the index date
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed